Gregory Oshanick
Brain Injury Medicine · North Chesterfield, VANPI 1982832960
Payments from drug & device makers
Across 273 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- Lundbeck LLC$366
- Pfizer$339
- Teva Pharmaceuticals USA, Inc.$175
- Axsome Therapeutics, Inc.$139
- plus $785 from 15 others
What the payments were for
- Consulting fees$2,04035%
- Food & beverage$3,60962%
- Education$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $2,105 |
| AbbVie(2 entities) | 184 | $1,898 |
| Lundbeck LLC | 20 | $366 |
| Pfizer | 17 | $339 |
| Teva Pharmaceuticals USA, Inc. | 5 | $175 |
| Axsome Therapeutics, Inc. | 7 | $139 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $107 |
| Biohaven Pharmaceuticals, Inc. | 3 | $89 |
| Bausch Health US, LLC | 4 | $88 |
| Eisai Inc. | 1 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Harmony Biosciences LLC | 2 | $48 |
| UCB, Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Impel Pharmaceuticals Inc. | 2 | $32 |
| Biogen | 1 | $22 |
| Amgen | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
| TMS Neurohealth Centers Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$2,040
How this compares
Too few brain injury medicine providers in Virginiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 27 | $25,215 |
| VraylarCariprazine Hcl | 14 | $21,445 |
| Lamictal XrLamotrigine | 12 | $20,786 |
| Keppra XrLevetiracetam | 12 | $18,630 |
| NexiumEsomeprazole Magnesium | 16 | $10,927 |
| LamictalLamotrigine | 13 | $9,589 |
| Memantine Hcl ErMemantine Hcl | 16 | $1,638 |
| Gabapentin | 46 | $824 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $619 |
| Aripiprazole | 23 | $582 |
| Baclofen | 16 | $403 |
| Lamotrigine | 25 | $380 |
| Eszopiclone | 18 | $369 |
| Bupropion XlBupropion Hcl | 14 | $336 |
| Methylphenidate Hcl | 12 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $107 | $25,21527 claims |
| AbbVieVraylar | $1,898 | $21,44514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few brain injury medicine providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other brain injury medicine in North Chesterfield
- Samuel ClantonRichmond$930
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.